Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers

Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resistance in these tumours, here we conduct a large-scale m...

Descripción completa

Detalles Bibliográficos
Autores principales: Schuster, Eugene F., Lopez-Knowles, Elena, Alataki, Anastasia, Zabaglo, Lila, Folkerd, Elizabeth, Evans, David, Sidhu, Kally, Cheang, Maggie Chon U., Tovey, Holly, Salto-Tellez, Manuel, Maxwell, Perry, Robertson, John, Smith, Ian, Bliss, Judith M., Dowsett, Mitch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328947/
https://www.ncbi.nlm.nih.gov/pubmed/37419892
http://dx.doi.org/10.1038/s41467-023-39613-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10328947/
https://www.ncbi.nlm.nih.gov/pubmed/37419892
http://dx.doi.org/10.1038/s41467-023-39613-z

Ejemplares similares